Detalhe da pesquisa
1.
MRVAS Score-introducing a standardized magnetic resonance scoring system for assessing the extent of inflammatory burden in giant cell arteritis.
Rheumatology (Oxford)
; 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38305463
2.
CXCR4-directed PET/CT with [68 Ga]Ga-pentixafor in solid tumors-a comprehensive analysis of imaging findings and comparison with histopathology.
Eur J Nucl Med Mol Imaging
; 51(5): 1383-1394, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38082196
3.
Chemokine receptor-targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [18F]FDG.
Eur J Nucl Med Mol Imaging
; 51(3): 749-755, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37943339
4.
Lack of repeatability of radiomic features derived from PET scans: Results from a 18 F-DCFPyL test-retest cohort.
Prostate
; 83(6): 547-554, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36632656
5.
Test-retest repeatability of organ uptake on PSMA-targeted 18 F-DCFPyL PET/CT in patients with prostate cancer.
Prostate
; 83(12): 1186-1192, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37211963
6.
Individual radiosensitivity reflected by γ-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy.
Eur J Nucl Med Mol Imaging
; 50(2): 602-612, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36136101
7.
Molecular imaging of arterial fibroblast activation protein: association with calcified plaque burden and cardiovascular risk factors.
Eur J Nucl Med Mol Imaging
; 50(10): 3011-3021, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37147478
8.
SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T.
Eur J Nucl Med Mol Imaging
; 50(11): 3465-3474, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37272956
9.
Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients.
Eur J Nucl Med Mol Imaging
; 50(12): 3765-3776, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37474735
10.
Image acquisition and interpretation of 18F-DCFPyL (piflufolastat F 18) PET/CT: How we do it.
Can J Urol
; 30(1): 11432-11437, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36779950
11.
Performance Evaluation of a Preclinical SPECT Scanner with a Collimator Designed for Medium-Sized Animals.
Mol Imaging
; 2022: 9810097, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35903250
12.
In Vivo Functional Assessment of Sodium-Glucose Cotransporters (SGLTs) Using [18F]Me4FDG PET in Rats.
Mol Imaging
; 2022: 4635171, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35903251
13.
High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with 18F-DCFPyL.
Mol Imaging
; 2022: 7056983, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35283693
14.
Pretherapeutic estimated glomerular filtration rate predicts development of chronic kidney disease in patients receiving PSMA-targeted radioligand therapy.
Prostate
; 82(1): 86-96, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34633090
15.
177 Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: An updated systematic review and meta-analysis.
Prostate
; 82(7): 826-835, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35286735
16.
Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy.
Prostate
; 82(14): 1406-1412, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35860909
17.
CXCR4-targeted theranostics in oncology.
Eur J Nucl Med Mol Imaging
; 49(12): 4133-4144, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35674738
18.
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
Eur J Nucl Med Mol Imaging
; 49(9): 3269-3276, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35243517
19.
Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens.
Eur J Nucl Med Mol Imaging
; 49(11): 3938-3949, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35556160
20.
Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up.
Eur J Nucl Med Mol Imaging
; 49(12): 4262-4270, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35650263